Carbamazepine Biosensor Development for Epilepsy Patient Screening

Pino, Esteban J.; Pucheu, Francisca; Alvarado, Fabian; Gómez, B Fraile; Diego, Marta de; Mennickent, Sigrid; Aguayo, Claudio; Peña, C. Rodríguez; Rodríguez, Andrés

doi:10.1109/embc46164.2021.9629901

Cited by 1 publication

(1 citation statement)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The number and duration of EP attacks were effectively suppressed, suggesting that valproate sodium in combination with carbamazepine significantly affects treating EP. Similarly, this is consistent with the results of previous studies (Nevitt et al, 2018a, Pino et al, 2021, which can corroborate the results of the current experiment. It is well known that sodium valproate is a nitrogen-free broad-spectrum antiepileptic drug and one of the common drugs used in clinical practice for the treatment of EP and that the drug is mainly distributed in the extracellular fluid and mostly bound to plasma proteins in the blood (Li et al, 2019).…”

Section: Discussionsupporting

confidence: 94%

Untitled

2023

Pak. J. Pharm. Sci.,

View full text Add to dashboard Cite

To examine how sodium valproate and carbamazepine improve cognitive function and self-care in Epilepsy Patients (EP). Our facility collected 150 EP patients from September 2020 until June 2022. 70 patients received carbamazepine as the control group, and 80 received it with sodium valproate as the observation group. Both groups recorded EP attack frequency and duration following treatment to compare clinical efficacy. The Nerve Growth Factor (NGF) and Brain-Derived Neurotrophic Factor (BDNF) were measured before and after treatment, adverse effects were counted, and the patient's ability to perform activities of daily living and activities was assessed by Montreal Cognitive Assessment (MOCA), Activities of Daily Life (ADL), and Barthel Index (BI). The observation group had fewer EP episodes and shorter EP episodes than the control group (P<0.05), and the total effective rate of treatment was greater. After treatment, Nerve Growth Factor and Brain Derived Neurotrophic Factor were higher in the observation group than in the control group (P<0.05). The observation group had fewer adverse effects than the control group (P<0.05). The observation group outperformed the control group in MOCA, ADL, and BI after treatment (P<0.05). Valproate with carbamazepine can reduce EP attacks and improve clinical efficacy and safety.

show abstract

Section: Discussionsupporting

confidence: 94%

Untitled

2023

Pak. J. Pharm. Sci.,

View full text Add to dashboard Cite

show abstract

Carbamazepine Biosensor Development for Epilepsy Patient Screening

Cited by 1 publication

References 9 publications

Untitled

Untitled

Contact Info

Product

Resources

About